Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Moodys
McKesson
Medtronic
Harvard Business School

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

OPTIRAY 300 Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Optiray 300 patents expire, and what generic alternatives are available?

Optiray 300 is a drug marketed by Liebel-flarsheim and is included in two NDAs.

The generic ingredient in OPTIRAY 300 is ioversol. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ioversol profile page.

Drug patent expirations by year for OPTIRAY 300
Recent Clinical Trials for OPTIRAY 300

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
MallinckrodtPhase 4

See all OPTIRAY 300 clinical trials

Pharmacology for OPTIRAY 300
Synonyms for OPTIRAY 300
1-N,3-N-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-(2-hydroxyethyl)amino]-2,4,6-triiodobenzene-1,3-dicarboxamide
1,3-Benzenedicarboxamide, N,N'-bis(2,3-dihydroxypropyl)-5-((hydroxyacetyl)(2-hydroxyethyl)amino)-2,4,6-triiodo-
771I402
8771-40-2
87771-40-2
AB00513943
AB00513943_02
AC-536
AC1L1GLW
AC1Q4PBO
AKOS015896385
AMDBBAQNWSUWGN-UHFFFAOYSA-N
AN-15742
API0003020
AS-12851
BC215938
BCP11109
BPBio1_001051
BRD-A65818372-001-01-2
BRN 7155654
BSPBio_000955
C18H24I3N3O9
CAS-87771-40-2
CCG-213209
CHEBI:31717
CHEMBL1200614
CS-7483
CTK3E8473
D01555
DB09134
DSSTox_CID_25521
DSSTox_GSID_45521
DSSTox_RID_80927
DTXSID2045521
FT-0627284
HMS1570P17
HMS2097P17
HMS3714P17
HY-B1410
I06-1983
ioversol
Ioversol (JAN/USP/INN)
Ioversol [USAN:INN:BAN]
Ioversol [USAN:USP:INN:BAN]
Ioversolum
Ioversolum [Latin]
LOVERSOL
LS-29726
MolPort-005-938-391
MP 328
MP-328
N,N'-Bis (2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl) -glycolamido] -2,4,6-triiodoisophthalamide
N,N'-Bis(2,3-dihydroxypropyl)-5-(N-(2-hydroxyethyl)glycolamido)-2,4,6-triiodoisophthalamide
N,N'-bis(2,3-dihydroxypropyl)-5-[(hydroxyacetyl)(2-hydroxyethyl)amino]-2-1,3-benzenedicarboxamide
n,n'-bis(2,3-dihydroxypropyl)-5-[glycoloyl(2-hydroxyethyl)amino]-2,4,6-triiodoisophthalamide
N1,N3-bis(2,3-dihydroxypropyl)-5-(2-hydroxy-N-(2-hydroxyethyl)acetamido)-2,4,6-triiodoisophthalamide
N1,N3-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-(2-hydroxyethyl)amino]-2,4,6-triiodo-benzene-1,3-dicarboxamide
N3RIB7X24K
NCGC00016956-01
NCGC00179364-01
NCGC00179364-03
NSC-760064
NSC760064
Optiray
Optiray (TN)
Optiray 160
Optiray 240
Optiray 320
Optiray 350
P 530
Pharmakon1600-01503837
Prestwick0_000878
Prestwick1_000878
Prestwick2_000878
Prestwick3_000878
Q-201247
SCHEMBL24711
SPBio_002876
SR-01000872680
SR-01000872680-1
Tox21_110709
Tox21_110709_1
UNII-N3RIB7X24K

US Patents and Regulatory Information for OPTIRAY 300

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Liebel-flarsheim OPTIRAY 300 ioversol INJECTABLE;INJECTION 019710-004 Jan 22, 1992 RX Yes Yes   Start Trial   Start Trial   Start Trial
Liebel-flarsheim OPTIRAY 300 ioversol INJECTABLE;INJECTION 020923-004 May 13, 1999 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Baxter
Colorcon
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.